CD4 + T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and Switzerland

Journal of Infectious Diseases

Volumn 200, Issue 11, 2009, Pages 1729-1735

  May, Margaret ^a   Wood, Robin ^b   Myer, Landon ^c,d   Taffé, Patrick ^e   Rauch, Andri ^f   Battegay, Manuel ^h   Egger, Matthias ^a,g  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b Institute of Infectious Disease and Molecular Medicine   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Columbia University ^*  (United States)

^e Data Centre   (Switzerland)

^f University Hospital Inselspital   (Switzerland)

^g UNIVERSITY OF BERN   (Switzerland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CORRELATION ANALYSIS; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; SOUTH AFRICA; SURVIVAL RATE; SWITZERLAND;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MODELS, STATISTICAL; SOUTH AFRICA; SWITZERLAND;

EID: 72849110184     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/648096     Document Type: Article

References (35)

1. Gottlieb GS, Sow PS, Hawes SE, et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002; 185:905-914
2. Phillips AN, Pezzotti P, Lepri AC, et al. CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: evidence from the Italian Seroconversion Study. AIDS 1994; 8:1299-1305 (Pubitemid 24267754)
3. Lepri AC, Sabin CA, Phillips AN, Lee CA, Pezzotti P, Rezza G. The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. Epidemiol Infect 1998; 121: 369-376 (Pubitemid 28493155) (Pubitemid 28493155)
4. Wandel S, Egger M, Rangsin R, et al. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect 2008; 84(Suppl 1):i31-i36.
5. World Health Organization (WHO). Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2008. Geneva:World Health Organization, UNAIDS, Unicef; 2008.
6. Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42: 464-469 (Pubitemid 44050895) (Pubitemid 44050895)
7. Duvignac J, Thiebaut R. CD4 natural history and informative censoring in sub-Saharan Africa. J Acquir Immune Defic Syndr 2006; 43:380-381 (Pubitemid 44674024) (Pubitemid 44674024)
8. Touloumi G, Pocock SJ, Babiker AG, Darbyshire JH. Estimation and comparison of rates of change in longitudinal studies with informative drop-outs. Statistics in Medicine 1999; 18:1215-1233 (Pubitemid 29229711) (Pubitemid 29229711)
9. Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS 2003; 17:541-545 (Pubitemid 36293107) (Pubitemid 36293107)
10. Badri M, Ehrlich R, Pulerwitz T, Wood R, Maartens G. Tuberculosis should not be considered an AIDS-defining illness in areas with a high tuberculosis prevalence. Int J Tuberc Lung Dis 2002; 6:231-237 (Pubitemid 34270101)
11. Badri M, Ehrlich R, Wood R, Maartens G. Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS 2001; 15:1143-1148 (Pubitemid 32549865) (Pubitemid 32549865)
12. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315: 1194-1199 (Pubitemid 27478210)
13. Sudre P, Rickenbach M, Taffe P, Janin P, Volkart AC, Francioli P. Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000. Schweiz Med Wochenschr 2000; 130: 1493-1500
14. Staehelin C, Rickenbach M, Low N, et al. Migrants from sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS 2003; 17:2237-2244 (Pubitemid 37338897) (Pubitemid 37338897)
15. Taffe P, May M. A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort. Stat Med 2008; 27: 4835-4853
16. Porter K, Babiker A, Walker S, et al. Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE. AIDS 2000; 14: 1899-1906 (Pubitemid 30688582) (Pubitemid 30688582)
17. Lindback S, Brostrom C, Karlsson A, Gaines H. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 × 10(6)/l, AIDS, and death from AIDS? BMJ 1994; 309:1535-1537
18. Vanhems P, Lambert J, Cooper DA, et al. Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis 1998; 26:323-329 (Pubitemid 28083941)
19. Easterbrook PJ, Farzadegan H, Hoover DR, et al. Racial differences in rate of CD4 decline in HIV-1-infected homosexual men. AIDS 1996; 10:1147-1155 (Pubitemid 26283354)
20. Mekonnen Y, Geskus RB, Hendriks JC, et al. Low CD4 T cell counts before HIV-1 seroconversion do not affect disease progression in Ethiopian factory workers. J Infect Dis 2005; 192:739-748 (Pubitemid 41193071) (Pubitemid 41193071)
21. Muller V, von Wyl V, Yerly S, et al. African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. AIDS 2009; 23:1269-1276
22. Madec Y, Boufassa F, Porter K, Meyer L. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS 2005; 19:2001-2007 (Pubitemid 41669025)
23. Ghys PD, Walker N, McFarland W, Miller R, Garnett GP. Improved data, methods and tools for the 2007 HIV and AIDS estimates and projections. Sex Transm Infect 2008; 84(Suppl 1):i1-i4.
24. Urassa W, Bakari M, Sandstrom E, et al. Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania. AIDS 2004; 18:433-438 (Pubitemid 38365870) (Pubitemid 38365870)
25. Aina O, Dadik J, Charurat M, et al. Reference values of CD4 T lymphocytes in human immunodeficiency virus-negative adult Nigerians. Clin Diagn Lab Immunol 2005; 12:525-530 (Pubitemid 41175321) (Pubitemid 41175321)
26. Lee BW, Yap HK, Chew FT, et al. Age- and sex-related changes in lymphocyte subpopulations of healthy Asian subjects: From birth to adulthood. Cytometry 1996; 26:8-15. (Pubitemid 3041283)
27. Maini MK, Gilson RJC, Chavda N, et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourinary Medicine 1996; 72:27-31. (Pubitemid 26057871)
28. Bisset LR, Lung TL, Kaelin M, Ludwig E, Dubs RW. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur J Haematol 2004; 72:203-212 (Pubitemid 38250798) (Pubitemid 38250798)
29. Wolday D, Tsegaye A, Messele T. Low absolute CD4 counts in Ethiopians. Ethiop Med J 2002; 40(Suppl 1):11-16
30. Ampofo W, Torpey K, Mukadi YD, et al. Normal CD4+ T lymphocyte levels in HIV seronegative individuals in the Manya/Yilo Krobo communities in the Eastern region of Ghana. Viral Immunol 2006; 19: 260-266 (Pubitemid 44050324) (Pubitemid 44050324)
31. Del Amo J, Petruckevitch A, Phillips A, et al. Disease progression and survival in HIV-1-infected Africans in London. AIDS 1998; 12:1203-1209 (Pubitemid 28302423) (Pubitemid 28302423)
32. Choudhary SK, Vrisekoop N, Jansen CA, et al. Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol 2007; 81:8838-8842 (Pubitemid 47242858) (Pubitemid 47242858)
33. Silvestri G, Paiardini M, Pandrea I, Lederman MM, Sodora DL. Understanding the benign nature of SIV infection in natural hosts. J Clin Invest 2007; 117:3148-3154 (Pubitemid 350096967) (Pubitemid 350096967)
34. Mandl JN, Barry AP, Vanderford TH, et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008; 14:1077-1087
35. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317: 944-947 (Pubitemid 47301321) (Pubitemid 47301321)